Major Shareholder Perceptive Advisors Appoints Managing Director to LeonaBio Board
LONA has more than doubled off its 52-week low of $3.6.
Summary
Perceptive Advisors, a 19.99% owner, has appointed its Managing Director, Fred Callori, to LeonaBio's board, indicating increased investor oversight and strategic involvement.
Key Events · Ownership and Investor Activity · LONA
-
Board Appointment from Major Shareholder
Fred Callori, a Partner and Managing Director at Perceptive Advisors, was appointed to LeonaBio's board of directors on May 5, 2026.
-
Significant Investor Influence
Perceptive Advisors, along with Joseph Edelman, beneficially owns 1,882,370 shares, representing 19.99% of LeonaBio's outstanding common stock.
-
Beneficial Ownership Limitation
The reporting persons are subject to a 19.99% beneficial ownership limitation, restricting warrant/option exercises that would exceed this threshold without prior notice.
-
No Recent Transactions
None of the reporting persons have effected any transactions in LeonaBio common stock in the past sixty days.
Analysis · LONA · Life Sciences
Perceptive Advisors, a significant institutional investor holding 19.99% of LeonaBio's common stock, has appointed Fred Callori, a Partner and Managing Director at the firm, to the company's board of directors. This move signals increased active involvement and oversight from a major shareholder, potentially influencing future strategic decisions and corporate governance. While no shares were transacted, the direct board representation suggests a deeper commitment and alignment of interests between the large investor and the company.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $9.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.6M. The 52-week trading range was $3.60 to $50.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.